HEMATOLOGY

Comprehensive insight on the sequencing of agents in BPDCN management, followed by considerations for use of stem cell transplant in this setting.

A review of the treatment armamentarium for patients with myelofibrosis in the context of clinical trial data supporting use of these agents.

Shifting their attention to myelofibrosis, Rami S. Komrokji, MD, and Pankit Vachhani, MD, define differences between various subsets of disease.

Centering discussion on the third patient case, panelists review second-line therapy options for those who relapse with blastic plasmacytoid dendritic cell neoplasm.

During a Targeted Oncology case-based roundtable event, Jeffrey E. Lancet, MD, discussed the clinical presentation of blastic plasmacytoid dendritic cell neoplasm and how it came to be recognized as a distinct rare hematologic malignancy. This is the first of 2 articles based on this event.

Expert panelists review the case of a 22-year-old woman diagnosed with BPDCN and consider the role of first-line chemotherapy in this setting.

Before closing out their review of polycythemia vera management, expert hematologist-oncologists highlight novel therapies in the pipeline.

Closing out their discussion on the first patient case of BPDCN, panelists consider which factors best inform the optimal selection of frontline therapy.

Considerations for the selection of optimal therapy in patients with polycythemia vera, and how these novel agents may be sequenced in the event of disease progression.

A brief review of the identification and management of capillary leak syndrome in patients being treated for blastic plasmacytoid dendritic cell neoplasm.

Expert perspectives on the first-line use of tagraxofusp, a CD123-directed therapy, in patients with blastic plasmacytoid dendritic cell neoplasm.

Centering discussion on polycythemia vera, Rami S. Komrokji, MD, and Pankit Vachhani, MD, share an in-depth review of cornerstone therapies in this setting.

Expert hematologist-oncologists share insight on the pathways driving myeloproliferative neoplasms and biomarkers that may be targeted with novel therapy.

In the prespecified interim analysis of the COMMANDS trial for low-risk myelodysplastic syndromes, luspatercept had statistically significant and clinically meaningful improvements in red blood cell transfusion independence with no new safety signals.

Centering discussion on the first patient case of BPDCN, expert panelists highlight various assessment tools that may help overcome barriers to an early diagnosis.

Shared insight on methods to identify blastic plasmacytoid dendritic cell neoplasm followed by updated classifications from the World Health Organization.

Broad perspective on diagnosis of the myeloproliferative neoplasms via optimal workup and molecular testing.

A comprehensive overview of myeloproliferative neoplasms followed by insight on the differences between essential thrombocytopenia, polycythemia vera, and myelofibrosis.

In an interview with Targeted Oncology, Nicholas J. Short, MD, discussed the evolution of the treatment landscape for acute lymphoblastic leukemia and what he hopes is next to come.

In an interview with Targeted Oncology, Tapan M. Kadia, MD, discussed the changes seen in the treatment landscape for patients with acute myeloid leukemia, specifically highlighting elderly and/or unfit patients.

At the 2022 NCCN: Hematologic Malignancies Conference, a panel discussion gave an overview of current treatment trends for acute myeloid leukemia, as well as supportive care measures to utilize during therapy.

Additional data emerged demonstrating the value of blinatumomab not only in patients with relapsed acute lymphoblastic leukemia but also in those with detectable minimal residual disease.

Phase 1 results examining azacitidine and venetoclax in high-risk myelodysplastic syndromes or chronic myelomonocytic leukemia elicited an overall response rate of 87%.

In comparison with conventional transplant options, Orca-T may be more effective with a lower probability of infection in patients with hematologic malignancies.

Jorge J. Castillo, MD, will explore the challenges of managing WM. He will present on September 30, 2022, at 11:04 AM.

Andrew A. Lane, MD, PhD, discusses the study design of a phase 1/2 trial of tagraxofusp-erzs for patients with blastic plasmacytoid dendritic cell neoplasms.

Lionel Adès, MD, PhD, discussed emerging targeted therapies for myelodysplastic syndromes during a presentation at the 10th Annual Meeting of the Society of Hematologic Oncology.

Combinations of the BCL2 inhibitor venetoclax with hypomethylating agents are undergoing investigation to determine benefit in high-risk myelodysplastic syndrome.

In the myeloma space, minimal residual disease negativity is prognostic of progression-free survival in relapsed or refractory patients. In leukemia, the biomarker combined with other prognostication techniques provides complex information that is clinically relevant.